| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H21ClFN7O4 |
| Molecular Weight | 489.887 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)C1=NN=C(O1)[C@H]2O[C@H]([C@H](O)[C@@H]2O)N3C=NC4=C3N=CN=C4NC5=CC=C(Cl)C=C5F
InChI
InChIKey=ZQYJPMPXQLNTPQ-QCUYGVNKSA-N
InChI=1S/C21H21ClFN7O4/c1-21(2,3)20-29-28-18(34-20)15-13(31)14(32)19(33-15)30-8-26-12-16(24-7-25-17(12)30)27-11-5-4-9(22)6-10(11)23/h4-8,13-15,19,31-32H,1-3H3,(H,24,25,27)/t13-,14+,15-,19+/m0/s1
| Molecular Formula | C21H21ClFN7O4 |
| Molecular Weight | 489.887 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
GW-493838 was developed by GlaxoSmithKline as an adenosine A1A receptor agonist for the treatment of dyslipidemia and neuropathic pain. GW493838 participated in the phase II clinical trial to determine the analgesic effect in patients with post-herpetic neuralgia or peripheral nerve injury caused by trauma or surgery. However, this study has been discontinued.
